HMI-115, a Potential First-in-Class Treatment for Endometriosis, Published Proof-of-Concept Phase II Clinical Trial Results in The Lancet Obstetrics, Gynaecology, & Women's Health - Fidelity
HMI-115, a Potential First-in-Class Treatment for Endometriosis, Published Proof-of-Concept Phase II Clinical Trial Results in The Lancet Obstetrics, Gynaecology, & Women's Health Fidelity
HMI-115, a Potential First-in-Class Treatment for Endometriosis, Published Proof-of-Concept Phase II Clinical Trial Results in The Lancet Obstetrics, Gynaecology, & Women's Health - PR Newswire
HMI-115, a Potential First-in-Class Treatment for Endometriosis, Published Proof-of-Concept Phase II Clinical Trial Results in The Lancet Obstetrics, Gynaecology, & Women's Health PR Newswire
Associations of PFAS exposure with obstetric and birth outcomes in the Japan Environment and Children's Study (JECS): Is maternal endometriosis an effect modifier?
Per- and polyfluoroalkyl substances (PFAS) are reportedly associated with adverse obstetric outcomes, including premature labor and gestational diabetes. We aimed to evaluate associations of maternal PFAS exposure with obstetric and …
Ferroptosis in reproductive system disorders: Pathological roles and therapeutic potential.
Ferroptosis, as an iron-dependent programmed cell death, plays a significant role in reproductive system diseases. It's involved in the pathological processes of various reproductive system diseases by affecting the survival …
Nanodrug impact on female reproductive health and fetal development: From translation approaches to long-term safety concern.
Biomaterials for drug delivery offer significant advantages over conventional medications, including enhanced cellular uptake, improved drug stability, targeted delivery, and controlled drug release. Cutting-edge nanodrugs delivery approaches such as drugs …